Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells

Area of Science:

• Endothelial Biology
• Molecular Pharmacology
• Cell Signaling

Background:

• Elevated intracellular cyclic guanosine monophosphate ([cGMP]i) inhibits cell growth and promotes apoptosis.
• Pulmonary endothelium comprises distinct cell types with potentially different responses to cGMP signaling.

Purpose of the Study:

• To investigate the role of phosphodiesterase type 5 (PDE5) in regulating intracellular cGMP levels in different pulmonary endothelial cell phenotypes.
• To determine how PDE5 activity influences endothelial cell growth, apoptosis, and response to atrial natriuretic peptide (ANP).

Main Methods:

• Primary cell culture of pulmonary arterial endothelial cells (PAECs) and pulmonary microvascular endothelial cells (PMVECs).
• Stimulation with ANP and measurement of intracellular cGMP levels.
• Pharmacological inhibition of PDE5 with zaprinast.
• Gene and protein expression analysis (RT-PCR, Western blot, immunoprecipitation).
• In vivo studies on extra-alveolar endothelium.

Main Results:

• PAECs express functional PDE5, leading to transient cGMP elevation after ANP stimulation.
• PMVECs lack PDE5, resulting in sustained cGMP elevation in response to ANP.
• PDE5 inhibition in PAECs mimicked the sustained cGMP response and induced growth inhibition and apoptosis, similar to PMVECs.
• ANP inhibited VEGF-induced proliferation and migration in PMVECs.

Conclusions:

• PDE5 is a key determinant of cGMP signaling dynamics in pulmonary endothelium.
• Differential expression and activity of PDE5 contribute to functional heterogeneity between PAECs and PMVECs.
• PDE5-mediated regulation of cGMP levels is critical for controlling endothelial cell growth, apoptosis, and vascular responses.